Overview of Hofseth BioCare ASA's Q3 2025 Performance
Hofseth BioCare ASA, also known as HBC, reported notable financial results for the third quarter of the fiscal year 2025. The total operating revenues stood at NOK 54.9 million, a decrease from NOK 67.9 million in the same quarter of the previous year. The decline in net operating revenues to NOK 54.8 million was largely attributed to lower commodity prices and a weaker U.S. dollar during the quarter.
Key Financial Highlights
For the quarter, HBC experienced an EBITDA of NOK -21.1 million, with the operational EBITDA at NOK -12.9 million, which excludes one-time strategic costs associated with clinical studies and research and development (R&D) expenses. This financial performance marks a critical period of adjustment as the company navigates through market challenges.
Liquidity and Financial Position
The company's cash and cash equivalents saw a decrease of NOK 2.6 million, concluding the period at NOK 65.5 million. Including available credit facilities, total liquidity reached NOK 67.0 million by the end of the quarter. Notably, a private placement successfully completed later has significantly bolstered HBC's equity and liquidity situation, setting a positive outlook for future operations.
Operational Milestones Achieved
Several highlights from the third quarter underscore HBC's operational success:
- The Midsund plant achieved new heights by processing 5,288 tonnes of raw material, establishing a record quarter for the company, thereby reinforcing its capacity of 24,000 tonnes per annum with consistent product quality.
- The gross margin showed improvement at 35%, rising from 28% due to a strategic shift towards high-value, specialty ingredients that cater to consumer demand.
- Significant growth was observed in Human Nutrition B2B sector with a staggering 200% year-over-year increase, fueled by the success of OmeGo® and ProGo® products. ProGo® notably clinched the NutraIngredients-USA “Healthy Aging” Award, enhancing its market reputation.
- In the realm of product innovation, the collagen ingredient NT-II™ was introduced to partners, receiving strong early feedback and gaining traction in hypoallergenic and weight-management formulations.
- Recent clinical studies for CalGo® showcased promising results in preventing bone loss while indicating a trend towards enhanced bone mass.
- AecorBio Inc., a subsidiary, has reported positive pre-clinical outcomes in areas such as oncology and asthma.
- In the B2C segment, revenues surged by 30%, supported by new European listings and the launch of key products on platforms like Amazon.de.
About Hofseth BioCare ASA
Founded on principles of sustainability and optimal resource utilization, Hofseth BioCare ASA is a Norwegian company dedicated to upcycling the by-products of the salmon industry. HBC transforms these materials into beneficial ingredients that promote health for both humans and pets. Their flagship products include ProGo®, a blend of bioactive peptides and collagen, and OmeGo®, a comprehensive salmon oil.
Moreover, HBC focuses on scientific rigor and credibility, fostering significant partnerships that support the operational strategy. Their findings have not only led to improved health benefits, such as enhanced iron metabolism and immune health, but also to innovations that could revolutionize treatment methodologies in various health conditions.
Contact Information
For additional inquiries or insights about Hofseth BioCare ASA, please reach out to:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
Frequently Asked Questions
What were Hofseth BioCare ASA's total operating revenues in Q3 2025?
The total operating revenues were NOK 54.9 million.
How did the EBITDA perform in Q3 2025?
EBITDA for the quarter was NOK -21.1 million.
What factors influenced the revenue changes noted in the financial report?
Lower commodity prices and a weaker U.S. dollar impacted net operating revenues.
Which product saw a notable increase in sales?
Sales for ProGo® and OmeGo® saw significant increases in the Human Nutrition B2B sector, with ProGo® earning an award for its innovation.
Where is Hofseth BioCare ASA headquartered?
The company's headquarters is in Ålesund, Norway, with operations in various global locations.
